Citizens Financial Group (CFG), with strategic insight into its investments and expansion plan, has consistently appeared in multiple bio-tech-centric occasions. CFG's role in the
2025 RBC Capital Markets Financial Institutions Conference highlighted its long-term determination in the industry. The group announced a
7.375% dividend yield on Series H preferred stock and ended 2024 with a strong Q4 reporting
$401M net income, yet their EPS slightly missed at
$0.83. Continued expansion to California and Florida hints at the company's growth initiatives, noted with the addition of middle-market regional executive and advisory teams. Regarding analyst perspectives, UBS, Citi, and Raymond James adjusted their price target, hold and buy rating on CFG stock respectively. CFG also cleared technical benchmark hitting a 90-Plus RS rating. With an ongoing commitment to execute robust consumer banking strategies, the position of Chief Experience Officer will see a change as Beth Johnson is set to retire. The group continues its commitment towards shareholders by announcing dividends and achieving an optimistic earnings call. Yet, certain indicators note caution for its near-term profitability though its private bank unit projected to be profitable in Q4.
Citizens Financial Group CFG News Analytics from Mon, 15 Apr 2024 07:00:00 GMT to Wed, 19 Feb 2025 18:05:00 GMT -
Rating 5
- Innovation -4
- Information 7
- Rumor -2
